RxDoctor Payments Data

Auxi Peachey, MD

Internal Medicine · Riverview, FLNPI 1356439509

Payments from drug & device makers

$1,391in general payments, 2019–2025

Across 30 payments — averaging $46.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$554
  • Amgen$138
  • GSK$130
  • Pfizer$128
  • Novartis$115
  • Paratek Pharmaceuticals, Inc.$114
  • plus $213 from 6 others

What the payments were for

  • Food & beverage$1,391100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,391 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$6,406
Medicare patients
21
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$35,437
JanumetSitagliptin Phos/Metformin Hcl15$23,890
JanuviaSitagliptin Phosphate13$18,381
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$17,270
Breo ElliptaFluticasone/Vilanterol32$13,007
Dabigatran EtexilateDabigatran Etexilate Mesylate16$5,941
Pregabalin21$4,169
Gabapentin135$4,025
Levemir FlexpenInsulin Detemir12$3,694
Atorvastatin Calcium336$2,805
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,248
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$2,049
Celecoxib25$1,671
LantusInsulin Glargine,hum.Rec.Anlog15$1,648
Pantoprazole Sodium95$1,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$35,43726 claims
GSKTrelegy Ellipta, Breo Ellipta$130$30,27657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →